CICC Healthcare Investment Fund
VC Fund
Beijing, China
CICC Healthcare Investment Fund is a healthcare investment vehicle of China’s CICC Capital.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries CICC Healthcare Investment Fund invests in
Stages CICC Healthcare Investment Fund invests in
Countries CICC Healthcare Investment Fund invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Huang Zhaohui
|
|||
4 more contacts available
Investment Focus
Industry
- Health Care 5 (50%)
- Biotechnology 4 (40%)
- Health Diagnostics 3 (30%)
- Medical 2 (20%)
- Biopharma 2 (20%)
Stage
- Series B 3 (30%)
- Venture - Series Unknown 3 (30%)
- Series A 1 (10%)
- Series C 1 (10%)
- Series D 1 (10%)
Country
- China 7 (70%)
- Israel 1 (10%)
- United States 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Huang Zhaohui
Managing Director
|
Managing Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NuProbe
|
An early stage molecular diagnostics company. | $50M / Series B / Jun 02, 2022 | |
|
NuProbe
|
An early stage molecular diagnostics company. | $50M / Series B / Jun 02, 2022 | |
Gloria spectrum
|
Gloria spectrum offers mass spectrometry applications as its core technology as well as multi-omics data-driven product innovation strategy. | Venture - Series Unknown / May 05, 2022 | |
Tianbing Technology
|
Tianbing Technology is an advanced aerospace propulsion system supplier and aerospace vehicle provider. Tianbing Technology independently develops the next-generation ambient temperature green HCP liquid propellant and minimalist aerospace propulsion system. As an upgraded product of traditional chemical propulsion system, it can meetcost-effective aerospace. Advance system supporting needs. The next-generation green HCP aerospace propulsion system, first tested by Tianbing Technology, can be used in the small-vehicle main power and launch vehicle upper-level propulsion system. | $15.7M / Series B / Feb 09, 2022 | |
Chemsemi
|
ChemSemi develops 5G chips and semiconductor technologies. | $157.8M / Series A / Jan 21, 2022 | |
MicroPort NeuroTech
|
MicroPort NeuroTech is a medical device company that specializes in neurological intervention. It develops innovative products that deliver safe, effective, and accurate solutions for patients with cerebrovascular diseases.MicroPort NeuroTech's unique products include WILLIS Intracranial Stent Graft System, APOLLO Intracranial Stent System,and Tubridge Vascular Reconstruction Device for treatments. The products promote therapeutic options adapted to specific needs. MicroPort NeuroTech was founded on May 2012 and is based in Shanghai, China. | $150M / Venture - Series Unknown / Nov 12, 2021 | |
Changmugu Medical
|
Changmugu Medicalis an artificial intelligence (AI)-powered healthcare start-up providing AI-powered surgical robot solutions. | $84.5M / Series B / Nov 10, 2021 | |
Thousand Oaks Biopharmaceuticals
|
Thousand Oaks Biopharmaceuticals is a developer of biopharmaceutical technologies intended to produce protein and vaccine compounds. The company's technologies provide integrated control solutions, including the use of technical expertise to optimize the process and increase protein expression to reduce production scale, providingbio-pharmaceutical companies with personalized, chemical-defined cell culture media, formula production, technical support and ancillary services. | $61.5M / Series C / Mar 10, 2021 | |
MitrAssist
|
MitrAssist introduces a minimally invasive approach to MR treatment. Its mitral valve implant works in unison with the natural mitral valve without harming its functionality.MitrAssist has developed a new approach to treating MR that is neither repair nor replacement. Instead, its proprietary valve implant is placed on top of the natural valveto work in unison with it and to enhance valve functionality.MitrAssist’s “valve-in-valve” approach overcomes the various challenges of MR and offers an improved treatment solution for all MR patients. It has significant advantages over minimally invasive solutions – both existing and in development. | $50M / Venture - Series Unknown / Dec 03, 2020 | |
Genetron Health
|
Genetron Health is a world-leading expert in precision medicine.They are committed to developing health management products that cover all elements of full-cycle cancer clinical treatment (including risk assessment, early screening, molecular pathology diagnosis, medication guidance and prognosis monitoring) and effectively applying genomic data toassist medical experts and research scientists. Additionally, they provide cancer patients and high-risk and healthy individuals with reliable molecular clinical services and professional cancer genetic risk assessment.In just three years, Genetron Health has built global genomics sequencing and bioinformatics platforms, established two research and development centers in both North Carolina, U.S., and Beijing, China, and set up clinical laboratories in Beijing, Shanghai, Hangzhou and Chongqing of over 10,000 square meters.In the future, Genetron Health will spread its sales network throughout China with professional marketing, product management, medical experts and scientific research teams, and will provide service for Chinese and global cancer patients with its strong foundation in cancer genomics and efficient clinical translation. | $71M / Series D / Nov 21, 2019 |
Co-Investors
BioTrack Capital
2 deals together
CDH Investments
2 deals together
CR-CP Life Science Fund
2 deals together
HSG
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does CICC Healthcare Investment Fund invest in?
CICC Healthcare Investment Fund invests primarily in Health Care, Biotechnology and Health Diagnostics startups, most often at Series B and Venture - Series Unknown stage. Most of the 10 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact CICC Healthcare Investment Fund?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at CICC Healthcare Investment Fund?
The team at CICC Healthcare Investment Fund includes Huang Zhaohui (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
